Show simple item record

dc.contributor.authorColdiron, ME
dc.contributor.authorGuindo, O
dc.contributor.authorMakarimi, R
dc.contributor.authorSoumana, I
dc.contributor.authorMatar Seck, A
dc.contributor.authorGarba, S
dc.contributor.authorMacher, E
dc.contributor.authorIsanaka, S
dc.contributor.authorGrais, RF
dc.date.accessioned2018-05-22T14:55:57Z
dc.date.available2018-05-22T14:55:57Z
dc.date.issued2018-05-08
dc.date.submitted2018-05-18
dc.identifier.citationSafety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial. 2018 Vaccineen
dc.identifier.issn1873-2518
dc.identifier.pmid29752026
dc.identifier.doi10.1016/j.vaccine.2018.05.023
dc.identifier.urihttp://hdl.handle.net/10144/619161
dc.description.abstractRotavirus remains a major cause of diarrhea among children under 5 years of age. The efficacy of RotaSIIL, a pentavalent rotavirus vaccine, was shown in an event-driven trial in Niger. We describe the two-year safety follow-up of this trial.
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/journal/0264410Xen
dc.rightsPublished by Elsevier Archived on this site with kind permission and copyright 200X from Elsevieren
dc.titleSafety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trialen
dc.identifier.journalVaccineen
refterms.dateFOA2019-03-04T13:56:59Z
html.description.abstractRotavirus remains a major cause of diarrhea among children under 5 years of age. The efficacy of RotaSIIL, a pentavalent rotavirus vaccine, was shown in an event-driven trial in Niger. We describe the two-year safety follow-up of this trial.


Files in this item

Thumbnail
Name:
Coldiron et al - 2018 - Safety ...
Size:
595.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record